The agreement gives Navilyst exclusive access to Interface Biologics’ Endexo technology.
Endexo is a self-locating bio-medical polymer additive that reduces platelet adhesion, protein adsorption and thrombus formation.
Navilyst Medical chairman and CEO Ron Sparks said that Endexo technology enhances the biocompatibility of the company’s vascular access products.
Navilyst Medical has introduced BioFloPICCs with Endexo Technology, following Canadian approval in August.
Interface Biologics is a developer of transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.